Procter & Gamble to acquire Thorne for $3.8 billion, CEO says
Procter & Gamble (P&G) agreed to acquire supplement maker Thorne for $3.8 billion, according to P&G CEO Shailesh Jejurikar, who said the deal would be announced later today on CNBC. Jejurikar said the move aims to expand P&G’s beauty and wellness business. Thorne was taken private in 2023 for $680 million and was projected to reach $650 million in sales in 2026, per CNBC.
How this was made
The 30-second read
Why it matters
A disclosed $3.8B acquisition agreement is likely to re-rate PG’s growth profile toward beauty and wellness, while also introducing deal execution and financing questions that can drive volatility around announcement details.
Market read
Traders can position for immediate M&A headline reaction in PG ahead of the later-today announcement, while monitoring deal terms and financing details not provided here.
What to watch
The article omits financing structure, regulatory review timing, and expected synergies, which are key drivers of post-announcement valuation and credit risk.
Background
Thorne, a supplement maker taken private in 2023, has been the subject of acquisition speculation for months.
Ticker impact
P&G agreed to acquire Thorne for $3.8 billion, with CEO Jejurikar disclosing the pending transaction on CNBC.
Near-term upside bias on deal enthusiasm, followed by volatility as traders price financing, regulatory risk, and synergy assumptions.
This is a first-report M&A agreement with a specific price and strategic rationale, which typically drives immediate repricing, though the article provides no financing terms or regulatory timeline.
Market effects
Consumer staples and personal care peers may see read-through on M&A appetite in beauty and wellness supplements.
Limited direct regional impact mentioned; UK-based Haleon and Unilever are cited only as potential speculated buyers.
Cross-border M&A interest in supplements could influence global category consolidation expectations.
Counterpoint
The headline deal price may be rich versus Thorne’s growth, and PG could face integration and margin risks that offset the strategic rationale.
Key entities
- companyProcter & Gamble
Agreed to acquire Thorne for $3.8 billion, expanding beauty and wellness via acquisitions.
- companyThorne
Supplement maker producing creatine and prenatal vitamins; on track for $650M sales in 2026 per CNBC.
- personShailesh Jejurikar
P&G CEO who disclosed the pending transaction during a CNBC appearance.
